Arcutis Biotherapeutics Inc (ARQT) saw an uptrend of 0.07% in the recent trading with $2190000.0 being its most recent. The current price level -22.48% lower than the highest price of $17.75 marked by the stock while trading over the past 52-weeks, whereas it is 75.06% higher than the lowest price of $7.86 the company dropped to over past 52-weeks. The latest news story on ARQT appeared in (GlobeNewswire) under the title “Arcutis’ ZORYVE (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis” on Jun-26-25.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 3 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
Arcutis Biotherapeutics Inc Earnings – What Happened With ARQT
Coming around sales and income figures on ARQT Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
Arcutis Biotherapeutics Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 119.14 million. ARQT does have institutional investors; and they hold 98.78% of the stock.
As on 2024-06-30, JENNISON ASSOCIATES LLC was the top most holder in Arcutis Biotherapeutics Inc (NASDAQ:ARQT) with an ownership of 11.57 million shares of the company or 9.3712 of the stake worth $107.62 million. The filing also reveals SUVRETTA CAPITAL MANAGEMENT, LLC as the second largest holder in the company with a control over 8.1021 of the outstanding shares. Its stake is worth $93.04 million for having 10.0 million shares in hand.
RUBRIC CAPITAL MANAGEMENT LP also came holding a key position in the company during the recent quarter and it now holds 7.95 of the outstanding shares. With this there are now 325.0 institutions which have possession in ARQT’s shares.
Key Metrics forARQT
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Arcutis Biotherapeutics Inc has a debt to equity ratio of 0.78.
Technical Analysis of Arcutis Biotherapeutics Inc (NASDAQ:ARQT) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Arcutis Biotherapeutics Inc (ARQT), we notice that the stock’s 20-day average volume is at 1,990,665 shares and 50% of short term indicators are suggesting the stock as Sell. And to end with, ARQT’s 100-day average volume are 2,347,564 shares.
